Trial Profile
Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms C-MAJOR
- Sponsors Otsuka Pharmaceutical
- 08 Feb 2024 Planned number of patients changed from 600 to 530.
- 08 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 08 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.